SWP
BCRX icon

Stratos Wealth Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Stratos Wealth Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Hold
14,700
– – ﹤0.01% 1643
2026
Q1 		$140K Hold
14,700
– – ﹤0.01% 1568
2025
Q4 		$115K Buy
+14,700
New +$106K ﹤0.01% 1547
2018
Q1 		– Sell
-1,000
Closed -$5K – 3116
2017
Q4 		$5K Buy
+1,000
New +$4.84K ﹤0.01% 2379

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Stratos Wealth Partners's BCRX Position: Q2 2026 in Review

Stratos Wealth Partners held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 14,700 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Stratos Wealth Partners first reported a position in BCRX in Q4 2017 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Stratos Wealth Partners held 14,700 shares of BioCryst Pharmaceuticals worth $147K as of Q2 2026.
  • Stratos Wealth Partners left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1643 holding.
  • Stratos Wealth Partners first reported a position in BioCryst Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.